As a coalition of Canada's leading infectious disease institutions, the PREVENT team is well-positioned to safely and effectively facilitate vaccine mid-stage development, testing and taking projects forward to commercialization. Each year infectious diseases claim the lives of almost twice as many people as heart disease and more than three times that of various forms of cancer, demonstrating the need to adopt a strong and effective approach to technology transfer, and to take much needed vaccines into production.
This is the focus of the Pan-Provincial Vaccine Enterprise (PREVENT), a partnership of three of Canada's leading infectious disease clusters – (VIDO) Vaccine Infectious Disease Organization (University of Saskatchewan), (CCfV) Canadian Center for Vaccinology (Dalhousie University – IWK Health Centre – QE11 Health Sciences Centre), and (BCCDC) BC Centre for Disease Control (University of British Columbia), funded by the federal Centres of Excellence for Commercialization and Research Program. The PREVENT team works to establish a comprehensive preclinical and early clinical platform for the introduction of vaccines of high priority for the public health system. The team works closely with academia, industry, government and not-for-profit sectors to accelerate downstream vaccine development so that promising and much-needed vaccines can move readily into clinical development and production.